Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Syngene International Limited

SYNGENE · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹402.70

+₹4.10 (+1.03%)(1D)

₹344.4552 Week Range₹678.95

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

40/100

Valuation

0/100

Quality

31/100

Growth

56/100

Health

93/100

Momentum

36/100

Valuation
0
Quality
31
Growth
56
Health
93
Momentum
36

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Syngene International Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹402.7

Market cap

₹16,220 Cr

P/E ratio

87.16

P/B ratio

3.35

Dividend yield

Not available

ROE

Not available

RSI 14

58.65

1Y return

Not available

Syngene International Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Syngene International Limited (SYNGENE) stock page cover?

Syngene International Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for SYNGENE?

Syngene International Limited is currently shown with a delayed price near ₹402.7, P/E 87.16.

Does the SYNGENE page provide investment advice?

No. The SYNGENE page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

VIJAYA

Vijaya Diagnostic Centre Limited · Healthcare

METROPOLIS

Metropolis Healthcare Limited · Healthcare

LALPATHLAB

Dr. Lal Path Labs Ltd. · Healthcare

How to Use Anvest Intelligence Effectively: 10 Practical AI Stock Research Prompts

Master AI-assisted stock research on Indian equities. Learn how to construct grounded financial queries, audit concall guidance, verify filing citations, and avoid ungrounded AI hallucinations.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Syngene International is a leading integrated research, development, and manufacturing organization (CRDMO) based in India. It provides scientific services to pharmaceutical, biotechnology, nutrition, animal health, and consumer goods companies globally, helping them bring new products to market.

Diagnostics & ResearchGlobal FootprintFounded:1993CEO/MD:Jonathan HuntHQ:Bengaluru, Karnataka

Business profile as of 2026-08-25

Revenue growth: +2.6%FY26 growth+5.4%3Y CAGR
EPS growth: -36.2%FY26 growth-11.9%3Y CAGR
CFO / PAT: 2.89×FY26

What Looks Strong

Cash FlowOperating cash flow was 2.89× total net profit in FY26.

What to Watch

EarningsNet profit fell about 36% in FY26 (consolidated: ₹496 cr → ₹317 cr). Watch margins and one-off items in the next filing.
MarginsOperating margin compressed from ~16.7% to ~12.5% in FY26 (consolidated). Watch input costs and pricing in the next two results.
ValuationThe shares trade at 87× trailing earnings; the multiple assumes sustained high growth and is sensitive to any slowdown.
MarketShares have lagged the Nifty 500 by 25.3 percentage points annualized over three years.

Reports a single operating segment in its results filings.
The company operates across 4 campuses with 5,641 scientists and a total workforce of 8,235.
It holds over 400 patents for its customers and emphasizes sustainability with 95% hazardous waste recycled and 92% renewable power sourcing.

FY26 (consolidated): revenue ₹3,739 cr, up 3% from ₹3,642 cr in FY25; net profit ₹317 cr, down 36% from ₹496 cr in FY25.
FY26 (consolidated): operating cash flow ₹915 cr (2.9× net profit); debt/equity 0.09×.
Latest quarter to Sep 2026 (consolidated): revenue ₹833 cr (down 9% year on year); net profit ₹32.2 cr.